Shire PLC: Top line results of Lifitegrast in OPUS2 trial: disappointing

NEUTRAL, Fair Value 3100p vs. 3150p (+15%)

News published on December Friday 6, 2013
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities